Littérature scientifique sur le sujet « Nanocarrier Liposoma »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Nanocarrier Liposoma ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Nanocarrier Liposoma"
Marqués-Gallego, Patricia, et Anton I. P. M. de Kroon. « Ligation Strategies for Targeting Liposomal Nanocarriers ». BioMed Research International 2014 (2014) : 1–12. http://dx.doi.org/10.1155/2014/129458.
Texte intégralNikolova, Maria P., Enamala Manoj Kumar et Murthy S. Chavali. « Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment ». Pharmaceutics 14, no 10 (15 octobre 2022) : 2195. http://dx.doi.org/10.3390/pharmaceutics14102195.
Texte intégralYan, Wei, Sharon SY Leung et Kenneth KW To. « Updates on the use of liposomes for active tumor targeting in cancer therapy ». Nanomedicine 15, no 3 (février 2020) : 303–18. http://dx.doi.org/10.2217/nnm-2019-0308.
Texte intégralAndreana, Ilaria, Valeria Bincoletto, Maela Manzoli, Francesca Rodà, Vita Giarraputo, Paola Milla, Silvia Arpicco et Barbara Stella. « Freeze Drying of Polymer Nanoparticles and Liposomes Exploiting Different Saccharide-Based Approaches ». Materials 16, no 3 (31 janvier 2023) : 1212. http://dx.doi.org/10.3390/ma16031212.
Texte intégralYue, Xiuli, et Zhifei Dai. « Liposomal Nanotechnology for Cancer Theranostics ». Current Medicinal Chemistry 25, no 12 (19 avril 2018) : 1397–408. http://dx.doi.org/10.2174/0929867324666170306105350.
Texte intégralTansi, Felista L., Ronny Rüger, Ansgar M. Kollmeier, Markus Rabenhold, Frank Steiniger, Roland E. Kontermann, Ulf K. Teichgräber, Alfred Fahr et Ingrid Hilger. « Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes ». Pharmaceutics 12, no 4 (17 avril 2020) : 370. http://dx.doi.org/10.3390/pharmaceutics12040370.
Texte intégralFathalla, Dina, Eman M. K. Youssef et Ghareb M. Soliman. « Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin : Preparation, Comparative Evaluation and Clinical Assessment in Psoriatic Patients ». Pharmaceutics 12, no 5 (11 mai 2020) : 446. http://dx.doi.org/10.3390/pharmaceutics12050446.
Texte intégralAl-Mahmood, Sumayah. « Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations ». Clinical Cancer Drugs 6, no 1 (27 septembre 2019) : 3–7. http://dx.doi.org/10.2174/2212697x06666190318150757.
Texte intégralPerminaite, Kristina, Anna Maria Fadda, Chiara Sinico et Kristina Ramanauskiene. « Formulation of Liposomes Containing Royal Jelly and Their Quality Assessment ». Journal of Nanoscience and Nanotechnology 21, no 5 (1 mai 2021) : 2841–46. http://dx.doi.org/10.1166/jnn.2021.19053.
Texte intégralPandya, Tosha, Kaushika Kaushika Patel, Rudree Pathak et Shreeraj Shah. « Liposomal Formulations In Cancer Therapy : Passive Versus Active Targeting ». Asian Journal of Pharmaceutical Research and Development 7, no 2 (14 avril 2019) : 35–38. http://dx.doi.org/10.22270/ajprd.v7i2.489.
Texte intégralThèses sur le sujet "Nanocarrier Liposoma"
Munson, Jennifer Megan. « Novel nanocarriers for invasive glioma ». Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/41226.
Texte intégralKolter, Melanie [Verfasser], et Regine [Akademischer Betreuer] Süss. « Liposomal nanocarriers for curcumin delivery and evaluation of endocytic inhibitors ». Freiburg : Universität, 2018. http://d-nb.info/116018643X/34.
Texte intégralBarattin, Michela. « Development of nanocarriers with responsive interfacial properties for site-specific drug delivery ». Doctoral thesis, Università degli studi di Padova, 2016. http://hdl.handle.net/11577/3424682.
Texte intégralAlterazioni funzionali e morfologiche dell'endotelio vascolare del sistema linfatico, alterazioni micro-ambientali quali l'amplificazione del kit enzimatico, sovraespressione di recettori specifici, aumento del potenziale redox, temperatura e abbassamento del pH, sono caratteristiche tipiche dei tessuti tumorali. Queste caratteristiche possono essere sfruttate con successo per lo sviluppo di sistemi colloidali sopramolecolari in grado di direzionare passivamente o attivamente farmaci antitumorali al sito d'azione. In questo lavoro è stata indagata una nuova piattaforma liposomiale sensibile al pH per il direzionamento selettivo al tumore e assicurare l'accumulo del farmaco in concentrazione terapeutica adeguata. I liposomi sono stati decorati con un nuovo promotore di internalizzazione cellulare non-peptidico che simula l'azione dei peptidi naturali conosciuti dagli studi di letteratura. È stata messa a punto una nuova procedura di sintesi per ottenere il derivato dendronico oligoargininico da includere nel doppio strato lipidico dei liposomi. Il derivato TetraBoc-Arg (PBF) - [G-2] -distearoil glicerolo (Arg4-DAG) è costituito da un nucleo centrale di poliestere a cui le arginine sono state coniugate su un lato e che è stato terminato con una catena distearoil glicerolo dall'altro. La macromolecola risultante possiede un carattere anfifilico in virtù delle sue due frazioni combinate: 1) la coda idrofoba distearoil, elemento lipidico di ancoraggio per associazione al doppio strato lipidico, 2) la carica positiva conferita dalle arginine periferiche, che mimano i residui amminoacidici fondamentali del peptide TAT, conferendo così l'attività biologica del sistema. Gli intermedi e il prodotto finale sono stati caratterizzati da 1H, 13C NMR e spettrometria di massa. I liposomi ottenuti con un rapporto molare 2:1 HSPC/colesterolo sono stati generati con crescente rapporto del CPE rispetto ai lipidi, utilizzando la tecnica di ‘post-insertion’, che ha determinato l'aumento del potenziale zeta dei liposomi da +8 mV a +24 mV, all’aumentare del rapporto di CPE dall'1% al 4%, raggiungendo quindi il plateau. Le proprietà biologiche dei liposomi rivestiti con il CPE fluorescente sono state studiate su cellule tumorali HeLa. L’analisi citofluorimetrica e lo studio di microscopia confocale hanno confermato l'elevata capacità dei liposomi di associare con le cellule. Rispetto al liposomi nudi, è stata rilevata una maggiore efficienza di associazione alla cellula tumorale di 30 volte. I liposomi rivestiti col CPE hanno dimostrato una notevole capacità di veicolare albumina e calceina nel citosol. BSA è stata scelta come proteina modello, mentre calceina è stata scelta perché è una molecola fortemente idrofila, in modo da simulare il comportamento di farmaci idrosolubili. Entrambe le molecole sono state incorporate nel nucleo idrofilo di liposomi. La calceina non è stata rilasciata dai liposomi per almeno 16 giorni, mentre BSA è stata completamente rilasciata in 7 giorni. Al fine di conferire ai liposomi responsività ad alterazioni di pH per l'accesso controllato alle cellule tumorali, è stato sintetizzato un polimero sensibile, pH mPEG-oligosulphadimethoxine (mPEG5kDa-SDM8), mediante polimerizzazione radicalica di sulfadimetossina metacrilato su una catena di 2-bromo-isobutirril-methoxyPEG (MPEG-Br ) 5kDa. mPEG5kDa-SDM8 possiede un pKa di 7,12 che garantisce uno stato deprotonato con carica negativa a pH fisiologico (7.4) e uno stato neutro protonato a pH 6,5, che corrisponde all'ambiente tumorale. L’analisi di potenziale Zeta eseguita su liposomi decorati con Arg4-DAG e con il polimero mPEG5kDa-SDM8 ha confermato che la capacità di schermatura/deschermatura più finemente regolata si ottiene quando i due moduli sono equimolari, entrambi a 4% in moli rispetto al lipidi. Questa formulazione è risultata stabile anche in presenza di proteine del siero, che non alterano l'interazione carica-carica tra l'oligo-sulfadimetossina del pH del polimero reattivo e oligo-arginine del CPE come osservato mediante analisi potenziale zeta. Anche lo studio SPR ha confermato questo risultato, dimostrando l'associazione del polimero con i liposomi rivestiti col CPE a pH 7.4 e il rilascio a pH 6,5, che corrisponde ad una peghilazione fisica reversibile in condizioni controllabili. Infine, gli studi biologici hanno confermato la capacità del polimero pH sensibile di schermare il CPE sulla superficie liposomiale in condizioni fisiologiche (pH 7,4), che impedisce l'internalizzazione delle vescicole non responsive al pH sia non caricate, sia caricate con calceina, mentre il polimero espone il CPE sulla superficie dei liposomi in presenza di un ambiente acido che simula il tumore, consentendo l'ingresso ai liposomi nelle cellule e la veicolazione del loro contenuto a livello intracellulare.
Agarwal, Abhiruchi. « Nanocarrier mediated therapies for the gliomas of the brain ». Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/39468.
Texte intégralCureton, Natalie. « Development of nanocarriers for targeted drug delivery to the placenta ». Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/development-of-nanocarriers-for-targeted-drug-delivery-to-the-placenta(696cfc4f-0bd7-4fbe-9b23-d2b83a7fec7d).html.
Texte intégralKarim, Reatul. « Design of Nanocarriers to Deliver Small Hydrophobic Molecules for Glioblastoma Treatment ». Thesis, Angers, 2017. http://www.theses.fr/2017ANGE0055/document.
Texte intégralThe aim of this thesis was to develop nanocarriers for efficient delivery of two low molecular weight hydrophobic drugs, apigenin (AG) and a ferrocifen-derivative(FcTriOH) to glioblastoma (GBM) as potential therapeutic strategies. Firstly, two liposomes, a lipid nanocapsule (LNC), and a polymer-based nanocapsule were develope dand compared by their physicochemical characteristics, drug loading capacity, storage stability, stability in biological serum, drug release profiles, complement consumption and toxicity. Due to various advantageous characteristics, the LNCs were selected for further optimization. Secondly, the LNCs were surface functionalized by adsorbing a GBM-targeting cellpenetratingpeptide (CPP). The CPP concentration increased to significantly enhance LNCinternalization in human GBM cells. The uptake mechanisms observed in U87MG cellswere : micropinocytosis, clathrin-dependent and caveolin-dependent endocytosis. Moreover, the optimized CPP-functionalized LNCs were internalized preferentially in theGBM cells compared to normal human astrocytes. Additionally, the in vitro efficacy of the AG-loaded and FcTriOH-loaded LNCs was evaluated. The FcTriOH-loaded LNC-CPP showed the most promising activity with a low IC50 of 0.5 μM against U87MG cells. Intracerebral administration of the LNCs in a murine orthotopic U87MG tumor modelshowed possible toxic effects and the need for dose optimization. Finally, studies inmurine ectopic U87MG tumor model showed promising activity after parenteral administration of the FcTriOH-loaded LNCs. Overall, these results exhibit the promising activity of FcTriOH-loaded LNCs as potential alternative GBM therapy strategy
Luna, Arthur Cassio de Lima. « Potencial antitumoral da formulação lipossomal DODAC/fosfoetanolamina sintética no modelo de hepatocarcinoma ». Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-15122017-092710/.
Texte intégralSynthetic phosphoethanolamine (PHO-S) - a phosphomonoester - has shown relevant anticancer effects. However, the utilization of a carrier to encapsulate the PHOS in liposomes can maximize its availability in the tumor microenvironment, allowing an increase in its effectiveness. Thus, the present study has evaluated efficiency of PHO-S encapsulation in DODAC liposomes and its antitumor potential. The liposomes were prepared by ultrasonication and physico-chemically characterized. The cytotoxic effects were evaluated on B16F10 cells (murine melanoma), Hepa1c1c7 cells (murine hepatocellular carcinoma), Skmel-28 (human melanoma) and in endothelial cells HUVEC, after treatment with DODAC/PHO-S liposomes at different concentrations for 24 hours. The internalization of the liposomes and mitochondrial electrical potential were analyzed by confocal laser microscopy. Additionally, the expression of active caspases 3 and 8, receptor DR4, cytochrome c, p53 p53, p21, Bax, p27, CD44, CD90, Bcl-2 and cyclin D1 proteins was quantified by flow cytometry. For in vivo studies, C57BL/6J mice with hepatocellular carcinoma were treated with PHO-S, DODAC/PHO-S and DODAC, by intraperitoneal (IP) and intratumoral (IT) routes for 20 days. The results demonstrated that liposomes presented spherical aspect and high PHO-S encapsulation efficiency, as also promoted high cytotoxic effect - compared with PHO-S. Furthermore, in B16F10 and Hepa1c1c7 cells, the liposomes induced S and G2/M cell cycle arrest. Hepa1c1c7 cells showed greater sensitivity to the DODAC/PHO-S formulation, which were internalized until 6 hours and promoted a decrease in the expression of CD90, CD44, cyclin D1 and Bcl-2, an increase of de p53, p21, p27, Bax and active caspases 8 and 3 and the liberation of cytochrome c. The significant increase in the expression of active caspases 3 and 8, DR4 receptor and liberation of cytochrome c also occurred in B16F10 and Skmel-28 cells. In vivo results showed that DODAC/PHO-S liposomes and PHO-S did not induce nephrotoxicity, hepatotoxicity and cachexia. DODAC/PHO-S liposomes did not cause myelosuppression and hemolysis, presenting lower toxicity in relation to PHO-S - when administered by IP and IT routes. Moreover, treatment with DODAC/PHO-S (IT) and PHO-S (IT and IP) effectively decreased the number of cells in S phase. However, only DODAC/PHO-S liposomes significantly reduced the number of tumor foci, increasing area of necrosis, and also promoting an increase in gene expression of p53, cyclin B1 and caspases 8 and 3. The set of in vitro and in vivo results demonstrated that DODAC/PHO-S liposomal formulation was capable of maximizing the PHO-S antitumor effects, activating the intrinsic and extrinsic pathways of the apoptosis
Borin, Diego Becker. « PRODUÇÃO DE LIPOSSOMAS DE CREATINA, AVALIAÇÃO DA TOXICIDADE E DE EFEITO NEUROPROTETOR EM MODELO ANIMAL DE NEURODEGENERAÇÃO ». Centro Universitário Franciscano, 2017. http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/574.
Texte intégralMade available in DSpace on 2018-08-20T12:27:29Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Tese_DiegoBeckerBorin.pdf: 7060697 bytes, checksum: bbf39761011feb8708ec27ab4968daed (MD5) Previous issue date: 2017-03-27
The pathophysiology of neurodegenerative diseases is associated with neuronal loss or dysfunction, whose characteristics are determined due to cerebral area affected and progression of the disease. Creatine has physiological importance as energy buffer and storage having protective effects in animal models of neurodegenerative diseases. However, its permeability through the blood-brain barrier (BBB) is very low. The objective of this study is was developing a nanoliposome carrier to facilitate the delivery of creatine to the central nervous system (CNS), thus could potentiate the effects of creatine. In order to test the safety of liposomes toxicity, assays were performed in cell culture and in vivo, as well as analyzed in streptozotocin-induced (STZ) dementia model. The method of production of liposomes by ethanol injection, proved to be efficient, since particles with a polydispersion index (PDI) of 0,237, negative Zeta potential (-12.5 mV) and average size of 213 nm were obtained. The size was confirmed by transmission electron microscopy where spherical particles of 100-200 nm were observed. In in vitro toxicity assays, blank liposomes (without creatine - BL) as well as creatine liposomes (CrL) at concentrations of 0.02 and 0.2 mg/mL did not alter the viability of VERO cells cultured. It also did not alter viability of neural cells in hippocampal slices from adult rats. In toxicity assays in vivo, subchronic treatment with both liposomes did no changes hematological and biochemical markers in blood of young rats, but an increased in creatine concentrations were observed in the brains of CrL-treated animals was observed. In the animal model of STZ-induced dementia in adult mice, behavioral changes such as habituation memory deficit and long-term aversive memory were reversed by 21 days treatment with free creatine and CrL. The animals of the STZ groups did not present alterations in energetic metabolism enzymes in the hippocampus, but they showed a reduction in creatine levels in cerebral tissue, which was reversed by the treatment with free creatine and CrL. It is suggested from the results that CrL can be used safely, but further studies should be performed to verify its performance in other neurodegeneration models.
A fisiopatologia de doenças neurodegenerativas está associada à perda ou disfunção neuronal, cujas características são determinadas pela região onde ocorre a perda e pela velocidade de progressão da doença. A creatina possui importância fisiológica como mecanismo de reserva e tampão energético tendo efeitos protetores em modelos animais de doenças neurodegenerativas, apesar de possuir baixa permeabilidade através da barreira hematoencefálica (BHE). Assim, o objetivo do presente estudo foi desenvolver um carreador lipossomado para facilitar a entrega de creatina ao sistema nervoso central (SNC), e assim potencializar os efeitos da creatina livre. Com a finalidade de testar a segurança dos lipossomas testes de toxicidade em cultura de células e in vivo foram realizados, assim como testes em um modelo de demência induzido por estreptozotocina (STZ) para avaliar sua funcionalidade, também foi avaliada a concentração de creatina no SNC dos animais. O método de produção de lipossomas por meio da injeção de etanol demonstrou ser eficiente, pois foram obtidas partículas com índice de polidispersão (IPD) 0,237, potencial Zeta de -12,5 mV e tamanho médio de 213 nm. O tamanho foi confirmado por microscopia eletrônica de transmissão onde observou-se partículas esféricas de 100 a 200 nm. Nos testes de toxicidade in vitro, os lipossomas brancos (sem creatina - LB) bem como os lipossomas de creatina (LCr) nas concentrações de 0,02 e 0,2 mg/mL não alteraram a viabilidade de células em cultura da linhagem VERO, e tampouco de fatias da área cerebral hipocampo de ratos adultos. Nos testes de toxicidade in vivo, não foram observadas alterações com o tratamento subcrônico com ambos lipossomas em marcadores hematológicos e bioquímicos em ratos filhotes, porém foi observado um aumento nas concentrações de creatina no cérebro dos animais tratados com LCr. No modelo animal de demência induzido por STZ em camundongos adultos foram observadas alterações comportamentais como déficit de memória de habituação e aversiva de longo prazo ambas revertidas pelo tratamento de 21 dias com creatina livre e LCr. Os animais dos grupos STZ não apresentaram alterações em enzimas do metabolismo energético no hipocampo, porém apresentaram redução nos níveis de creatina, que foi revertido pelo tratamento com creatina livre e LCr. Sugere-se a partir dos resultados obtidos, que os LCr podem ser utilizados com segurança, porém mais estudos devem ser realizados para verificar seu desempenho em outros modelos de neurodegeneração.
Rodríguez, Amigo Beatriz. « Light-sensitive nanocarriers for drug delivery in photodynamic therapy ». Doctoral thesis, Universitat Ramon Llull, 2018. http://hdl.handle.net/10803/462210.
Texte intégralEsta tesis profundiza en el estudio de nanotransportadores como sistema de vehiculización y en algunos casos, liberación de fotosensibilizadores empleados en terapia fotodinámica. Se emplean dos nanotransportadores de naturaleza distinta: proteínas y liposomas. En primer lugar se han investigado los complejos formados entre hipericina y las proteínas apomioglobina y β-lactoglobulina. Se han estudiado las características fisicoquímicas y fotofísicas, evaluando la actividad antimicrobiana frente bacterias gram-positivas y gram-negativas. En ambas matrices proteicas el fotosensibilizador se encuentra mayoritariamente en forma monomérica, preservando sus propiedades fotofísicas y formando un complejo estable. En el caso de la β-lactoglobulina se estudia además, la formación del complejo con la adición del 20% de DMSO como co-solvente, lo que mejora las propiedades físicas pero sorprendentemente, empeora la capacidad antimicrobiana. Ambos complejos proteicos son efectivos contra bacterias gram-positivas, pero no contra gram-negativas. Además, se demuestra que la hipericina en la cavidad de la apomioglobina es capaz de realizar microscopía de super-resolución STED, mediante la cual se puede monitorizar los sitios de unión a las bacterias. Asimismo, se ha estudiado la β-lactoglobulina como portador dual de hipericina y ácido retinoico. En este último sistema multi-componente se evalúan las propiedades fotofísicas para verificar la formación y estabilidad del complejo. En segundo lugar, se desarrolla un nanovehículo para su uso en terapia combinada en el que se incorpora fármacos quimioterapéuticos convencionales con agentes fotosensibilizantes, para superar las resistencias y mejorar la eficacia de los tratamientos individuales. Con este objetivo, se han diseñado y estudiado dos formulaciones liposomales diferentes, ambas con el mismo fotosensibilizador, pero con diferentes agentes quimioterapéuticos. Se preparan las formulaciones bimodales con ambos agentes en el mismo vehículo además de sus homólogos unimodales, con la incorporación única de uno de los dos agentes. Se han evaluado las características fisicoquímicas, fotofísicas y fotobiológicas de las suspensiones bimodales y unimodales. La localización subcelular demuestra que cada principio activo se localiza en orgánulos diferentes desencadenando rutas de señalización celular diferentes, eludiendo los posibles mecanismos de resistencia. El tratamiento in vitro en células cancerígenas de estos sistemas tiene un efecto prometedor siendo al menos aditivo en comparación con los tratamientos individuales. Finalmente, se ha evaluado el potencial de la vehiculización activa mediante la unión covalente de un anticuerpo monoclonal en la superficie, lo que lleva a resultados ligeramente superiores para una de las dos formulaciones.
This thesis reports the study of nanocarriers as drug delivery systems for photosensitisers in photodynamic therapy. Proteins and liposomes are the two nanovehicles of different nature used for this purpose. Beginning with the proteins, the complexes formed between hypericin and the proteins apomyoglobin and β-lactoglobulin have been explored. The physicochemical and photophysical properties have been studied, as also assessing their photoantibacterial activity against Gram-positive and Gram-negative bacteria. In both protein scaffolds the photosensitiser is found mainly in monomeric form, preserving its fluorescence and singlet oxygen photosensitising properties and yielding a stable complex. In the case of β-lactoglobulin, the complex formation has also been tested with the addition of a 20% DMSO as a co-solvent, which improves the photophysical properties but surprisingly, worsens its antimicrobial activity. Both protein complexes are effective against Gram-positive but not against Gram-negative bacteria. Moreover, it has been proved that hypericin, inside the apomyoglobin cavity, can perform STED microscopy through which its localization in bacteria can be monitored. Additionally, the suitability of β-lactoglobulin as a dual carrier for hypericin and acid retinoic has also been exploited. In this last multi-component system, the photophysical properties have been evaluated to confirm the formation and complex stability. Secondly, a nanocarrier for its use in combined therapy has been developed, in which conventional chemotherapeutic drugs are combined with photosensitising agents to overcome resistance and improve the effectiveness of the individual treatments. For this purpose, two different liposome formulations have been designed and studied with a common photosensitiser but different anti tumour drugs. The bimodal formulations with both agents entrapped and their unimodal counterparts, having each drug loaded in separate liposomes, have been evaluated. The physicochemical, photophysical and photobiological properties of bimodal and unimodal suspensions have been studied. The subcellular localization shows different organelle accumulation by each agent, triggering different key signals transduction pathways, eluding the cellular resistance mechanisms. The treatment in vitro of these multi-component liposomes with cancer cells has a promising effect, since at least an additive outcome is observed when compared with the individual treatments. Finally, we have explored the potential of active targeting strategies by covalently linking a monoclonal antibody to the surface, leading to slightly greater outcomes for one of the liposomal formulations.
Dattani, Poonam. « Development and Characterization of LDV Peptide Targeted Nanocarriers for Paclitaxel Delivery : A Comparative Study of Micelles, Liposomes and Solid Lipid Nanoparticles ». Scholarly Commons, 2019. https://scholarlycommons.pacific.edu/uop_etds/3623.
Texte intégralLivres sur le sujet "Nanocarrier Liposoma"
Weissig, Volkmar. Liposomes : Methods and Protocols, Volume 1 : Pharmaceutical Nanocarriers. Humana Press, 2016.
Trouver le texte intégralChapitres de livres sur le sujet "Nanocarrier Liposoma"
Suntres, Zacharias E., et Abdelwahab Omri. « The Role of Liposomal Antioxidants in Oxidative Stress ». Dans Nanocarrier Technologies, 191–205. Dordrecht : Springer Netherlands, 2006. http://dx.doi.org/10.1007/978-1-4020-5041-1_11.
Texte intégralPalma Abriata, Juliana, Marcela Tavares Luiz, Giovanni Loureiro Raspantini, Patrícia Mazureki Campos et Juliana Maldonado Marchetti. « Liposomal Drug Carriers ». Dans Nanocarriers for Brain Targeting, 349–76. Includes bibliographical references and index. : Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429465079-12.
Texte intégralLe, Ngoc Thuy Trang, Linh Phuong Tran Pham, Diem Huong Tran Nguyen, Ngoc Hoang Le, Tuong Vi Tran, Cuu Khoa Nguyen et Dai Hai Nguyen. « Liposome-Based Nanocarrier System for Phytoconstituents ». Dans Novel Drug Delivery Systems for Phytoconstituents, 45–68. Boca Raton : Taylor & Francis, 2020. | “A CRC title, part of the Taylor & Francis imprint, a member of the Taylor & Francis Group, the academic division of T&F Informa plc.” : CRC Press, 2019. http://dx.doi.org/10.1201/9781351057639-3.
Texte intégralSonju, Jafrin Jobayer, Achyut Dahal et Seetharama D. Jois. « Liposome Nanocarriers for Peptide Drug Delivery ». Dans Peptide Therapeutics, 203–35. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04544-8_6.
Texte intégralSadhu, Piyushkumar K., Nirmal Shah et Hiral M. Manani. « Liposomes : As a Potential Drug Carrier ». Dans Nanocarriers : Drug Delivery System, 303–26. Singapore : Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_12.
Texte intégralBorin, D. B., et R. C. V. Santos. « A Brief Account of Liposomes for Brain Delivery ». Dans Nanocarriers for Brain Targeting, 333–48. Includes bibliographical references and index. : Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429465079-11.
Texte intégralPhillips, William, Beth Goins et Ande Bao. « Long-Circulating Liposomes with Attached Diagnostic Moieties : Application for Gamma and MR Imaging ». Dans Multifunctional Pharmaceutical Nanocarriers, 431–56. New York, NY : Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-76554-9_15.
Texte intégralDragićević, Nina. « Lipid-Based Vesicles (Liposomes) as Skin Delivery Systems ». Dans Invasomes as Drug Nanocarriers for Innovative Pharmaceutical Dosage Forms, 31–108. Boca Raton : CRC Press, 2021. http://dx.doi.org/10.1201/9781003187332-2.
Texte intégralJain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey et Suresh P. Vyas. « Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario ». Dans Research Anthology on Synthesis, Characterization, and Applications of Nanomaterials, 115–37. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-8591-7.ch006.
Texte intégralJain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey et Suresh P. Vyas. « Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario ». Dans Multifunctional Nanocarriers for Contemporary Healthcare Applications, 448–70. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-4781-5.ch017.
Texte intégralActes de conférences sur le sujet "Nanocarrier Liposoma"
Zhu, Dan, Zhuyuan Wang, Shenfei Zong, Xin Wu, Yuwei Pei, Peng Chen, Xueqin Ma et Yiping Cui. « Liposome-silver Nanoparticles Hybrid as a SERS Traceable Drug Nanocarrier ». Dans JSAP-OSA Joint Symposia. Washington, D.C. : OSA, 2013. http://dx.doi.org/10.1364/jsap.2013.19p_d4_6.
Texte intégralChernenko, T., R. Sawant, L. Quintero, V. Torchilin, M. Diem, P. M. Champion et L. D. Ziegler. « Non-Invasive Imaging of Modified Liposomal Pharmaceutical Nanocarriers by Raman Microscopy ». Dans XXII INTERNATIONAL CONFERENCE ON RAMAN SPECTROSCOPY. AIP, 2010. http://dx.doi.org/10.1063/1.3482503.
Texte intégralGrafals, Nilmary, Blanca I. Quiñoes-Diaz, Janixa Del Valle, Gabriel L. Barletta-Bonano et Pablo E. Vivas-Mejía. « Abstract 4409 : Developing brain tumor-specific gold-liposomal nanocarriers for a noninvasive delivery of microRNA inhibitors ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4409.
Texte intégralHalevas, E., T. A. Papadopoulos, A. Hatzidimitriou, D. Reid, A. Salifoglou et G. Litsardakis. « Synthesis, structural, physical and chemical characterization of hybrid magnetic liposome nanocarriers of novel antioxidants for targeted drug delivery ». Dans 2017 IEEE International Magnetics Conference (INTERMAG). IEEE, 2017. http://dx.doi.org/10.1109/intmag.2017.8007873.
Texte intégralSarker, Sunandita, Yiannis S. Chatzizisis, Srivatsan Kidambi et Benjamin S. Terry. « Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis ». Dans 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6869.
Texte intégralFerreira, Rodrigo, Christian Maibohm, Oscar F. Silvestre, Rosa Romero, Helder Crespo et Jana B. Nieder. « Few-Cycle Laser for the in Vitro Study of Cellular Bioenergetics during Therapeutic Treatment with the Anticancer Drug Doxorubicin in its Free and Liposomal Nanocarrier Form ». Dans 2019 Conference on Lasers and Electro-Optics Europe & European Quantum Electronics Conference (CLEO/Europe-EQEC). IEEE, 2019. http://dx.doi.org/10.1109/cleoe-eqec.2019.8871603.
Texte intégral